Abstract
Introduction
The application of drug-eluting stents (DES) is a landmark event of percutaneous coronary intervention (PCI). Compared with bare metal stents (BMS), DES is associated with a significantly reduced risk of restenosis and target-vessel revascularization (TVR) in patients undergoing PCI [1, 2] . Although the first generation DES showed a perfect solution at the beginning, meta-analysis and randomized controlled trials showed that the rate of very late (> 1 year) stent thrombosis (ST) was increased with first generation DES [3, 4] .
Paclitaxel-eluting stents (PES) and sirolimus--eluting stents (SES), are recognized as first generation DES, because they were first introduced to the market and approved. Thereafter, a number of DES was developed and introduced to the market, such as everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES). Generally, limus--based stents (LBS) and PES are the two kinds of DES most commonly used in clinical. These two kinds of coronary stents inhibit in stent restenosis by different pharmacological mechanisms. Paclitaxel is an antineoplastic drug interfering cell microtubule function [5, 6] . Paclitaxel alters the dynamic equilibrium between microtubules and alpha-and beta-tubulin by favoring the formation of abnormally stable microtubules [7] . In vivo studies showed that paclitaxel could inhibit neointimal proliferation at a very low blood concentration [8] .
On the other hand, limus can also inhibit neointimal proliferation. Sirolimus is a potent immunosuppressant agent, which induces expression of the cyclin-dependent kinase inhibitor, p27 kip1, blocks the cell cycle at the G1 to S phase [9] . Everolimus can also exert anti-proliferative effect by inhibiting cell proliferation and inducing cell cycle arrest in the late G1 stage [10] .
Given different pharmacological mechanisms, the clinical outcomes of PES and LBS may alter over time, especially in a long time period. However, there has been no meta-analysis comparing DES with respect to pharmacological mechanisms. A lot of meta-analyses have compared the 1 year clinical outcomes of SES, EES, and PES [11] [12] [13] . Thus, we performed this meta-analysis to compare the long time (2-5 years) efficacy and safety of the LBS and PES in patients with PCI.
Methods

Searching strategy
Electronic databases of PubMed, Cochrane, and EMBASE were searched for eligible randomized controlled clinical trials (RCTs). There was no limitation on languages and the last search was performed on 18 September 2012. The following key words were used "sirolimus", "everolimus", "zotarolimus", "paclitaxel", and "stent". The references lists of relative articles were also searched for additional trials.
Inclusion and exclusion criteria
Trials met the following inclusion criteria: 1) RCTs; 2) comparison of LBS and PES in patients with PCI; 3) clinical outcomes of 2 years follow-up or more. The trials met the following exclusion criteria: 1) subgroup results of RCTs; 2) non--randomized; 3) without clinical outcomes.
Data collection
Two reviewers independently collected data with a standard data-collection form and reached consensus on each item. The following data were collected: first author, publishing time, stent type, time of follow-up, number of participants, age, male, number of patients with diabetes, number of patients analyzable, target lesion revascularization (TLR), TVR, stent thrombosis (ST), all cause death, cardiac death, and myocardial infarction (MI).
Assessment of risk of bias
The methodological quality of eligible trials was assessed using the "risk of bias" tool, recommended by the Cochrane Collaboration. Adequate sequence generation, allocation concealment, blinding, incomplete outcome data addressed, and free of selective reporting were assessed. Each of the 5 items was grades as "yes", "no", or "unknown", representing "low", "high", or "uncertain of " risk.
Statistical analysis
The efficacy and safety endpoints of LBS and PES in this meta-analysis were TLR, TVR, ST, all cause death, cardiac death, and MI at 2, 3, 4, and 5 years of follow-up. Odds ratios (OR) and 95% confidence intervals (CI) were calculated as summary statistics. Pooled OR was calculated using the Mantel-Haenzel fixed effects model or DerSimonian-Laird random effects model. In the absence of heterogeneity across trials, fixed effects model was used, otherwise, we chose random effects model. The c 2 test was performed to test the heterogeneity across included trials, and a p < 0.10 showed a significant heterogeneity. For publication bias, a graphic funnel plot was used to detect the existence of publication bias. Subgroup analyses (SES vs. PES, EES vs. PES, ZES vs. PES) were 
Results
Trial flow
A number of 1286 records form databases and references lists were screened. After screening of titles and abstracts, 82 records were extracted for further evaluation. In the end, 23 eligible trials were included and analyzed. The detailed process of trial flow is shown in Figure 1 (flow chart).
Characteristics of eligible trials and risk of bias
A number of 23 trials and 19319 patients were included in our meta-analysis. There were 3 trials [14] [15] [16] Table 2 ). Most trials addressed the method for sequence generation and allocation concealment.
Clinical outcomes at 2 years
The 2-year follow-up results were available in 11 trials with 13251 participants. As for revascularization and ST, LBS was superior to PES at 2 years. There were 375 patients with LBS and 406 patients with PES received TLR at 2 years of follow-up (OR = 0.59, 95% CI 0.44-0.78; Fig. 2 ). LBS was also associated with lower risk of TVR (OR = 0.63, 95% CI 0.55-0.71) and ST (OR = 0.55, 95% CI 0.41-0.73). In subgroup analysis, both SES and EES showed a lower rate TLR and TVR compared with PES, but only EES was associated with a reduced risk of ST (OR = 0.33, 95% CI 0.20-0.52). In terms of safety, LBS was associated with a lower risk of MI (OR = 0.67, 95% CI 0.57-0.79), but LBS and PES showed equal results of all-cause death and cardiac death. Subgroup analysis revealed that EES and ZES reduced the risk of MI but not SES (Table 3 ).
In conclusion, compared with PES, LBS showed a lower risk of revascularization and ST at 2-year follow-up and significantly reduced the incidence of MI. As for subgroup analysis, SES and EES but not ZES were superior to PES in TLR, TVR and ST.
Clinical outcomes at 3 years
A total of 7 trials and 3718 patients were analyzed for 3-year clinical outcomes. LBS and PES had equal clinical outcomes at 3-year follow-up. (Table 3) .
Clinical outcomes at 4 years
Two trials reported 4-year follow-up clinical outcomes of 662 patients. In summary, LBS showed lower risk of TLR (OR = 0.53, 95% CI 0.31-0.92) but similar risk of ST (OR = 1.35, 95% CI 0.46-3.98) compared to PES. Both LBS and PES showed similar safety, regarding the rate of cardiac death (OR = 0.58, 95% CI 0.20-1.63) and MI (OR = 0.69, 95% CI 0.26-1.84). In the presence of only 2 trials, subgroup analysis was not performed. LBS was associated a lower rate of TLR compared with PES at 4-year follow-up, but they did not differ significantly in other clinical outcomes (Table 3 ). (Table 3 ). In conclusion, there was no significant difference between LBS and PES at 5-year follow-up.
Heterogeneity and publication bias
Heterogeneity of major comparisons was tested and no severe heterogeneity existed across trials. Funnel plot of each comparison was performed and viewed for symmetry. All of the funnel plots were roughly symmetrical (figures not shown).
Discussion
This meta-analysis compared long time clinical outcomes of LBS and PES among patients undergoing PCI. We included 23 RCTs and 19319 patients, efficacy and safety of LBS and PES were analyzed at 2, 3, 4, and 5-year follow-up.
DES was a breakthrough technology in the invasive management of coronary artery diseases. LBS and PES are the two most common DES in clinical practice. As mentioned before, the neointimal proliferation pharmacological mechanisms differ significantly between LBS and PES [8] [9] [10] . Thus, it is reasonable to hypothesize that LBS and PES would have different clinical outcomes, especially over a long period of time. Pooled results from meta-analyses have showed that LBS and PES had different efficacy and safety at 1 year [11] [12] [13] , but comparison of long time period was rare. This meta-analysis firstly compared clinical outcomes of DES in a long time period and most importantly, we first compared different types of DES according to pharmacological mechanisms. We provided a new perspective of comparing coronary stents and the long time clinical results would be useful for development of new DES.
According to the comparison of 2-to 5-year clinical outcomes, we could find that clinical Heterogeneity: Chi = 1.89, df = 2 (P = 0.39); I = 0% Test for overall effect: Z = 0.42 (P = 0.67) outcomes of LBS and PES alter with time and LBS and PES have equally long time efficacy and safety. Previous meta-analyses have showed that LBS was associated with lower efficacy, such as ST and reintervention, compared with PES [11] [12] [13] . At 2 years, our meta-analysis results of 11 trials suggested that LBS still had the advantage over PES in the respect of efficacy (TLR, TVR, and ST); additionally, LBS was also associated with a reduced risk of MI. Subgroup analysis suggested that SES and EES significantly reduced the risk of revascularization compared with PES, but ZES was not statistically different from PES in most of the clinical outcomes. Especially EES was also associated with a reduced risk of ST compared with PES. At 3 and 5 years of follow-up, LBS and PES did not differ significantly in most of the clinical outcomes. What is of note is that ZES significantly reduced the risk of MI in comparison with PES. The 4-year comparison showed some discrepancy and we suspected that the cause was that too few trials were included. One important conclusion that can be drawn from our meta-analysis is that LBS is non-inferior to PES in terms of very long-time clinical outcomes. This adds to our knowledge about the longstanding clinical outcomes of stents and may change our opinions on the selection of stents. Thus far, only SES and EES were analyzed as LBS. In the comparisons of 5-year clinical outcomes, only trials comparing SES and PES were analyzed and trials comparing SES, EES and PES were included in the comparison of 3 and 4 years.
We also noticed that although LBS and PES had similar rate of all-cause death and cardiac death, the rate of MI was significantly lower with LBS at 2 and 3 years. This may be explained by the lower rate of ST in the patients with LBS. 
Limitations of the study
Limitations of this meta-analysis should also be noted before the application of the conclusion. Firstly, aggregate data were collected from each randomized trial and no further subgroup analysis could be performed, such as gender, age, smoking and other risk factors. Although the characteristics of participants of individual study were balanced, it was impossible for us to test whether the baseline characteristics were balanced between the groups. Secondly, trials with 4-and 5-year follow-up were rare and this may cause a discrepancy. The 3 trials analyzed for 5-year clinical outcomes were all designed to compare SES and PES, which also weakened the representativeness of LBS. Thirdly, the meta-analysis was based on randomized trials, not individual patient's data, and we could not assess the confounding factors.
Conclusions
Based on different pharmacological mechanisms, we systematically compared the long time clinical outcomes of LBS and PES. We found that LBS was associated with better efficacy (TLR, TVR, and ST) and lower rate of MI at 2 years, but comparisons of long time results revealed that both PES and LBS provided similar efficacy and safety. This meta-analysis as the first provides a long time systematical comparison of 2 different stents and it will be useful for future development of new DES.
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